ProQR Therapeutics N.V.(PRQR)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,221 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Unusual Activity in PRQR
Events flagged as statistical outliers against PRQR's own multi-year baseline — not fixed dollar thresholds.
- Insider cluster2026-07-31
2 insiders bought $1,111,385 of PRQR in 30 days — 3.9σ above this company's 2-year norm
View source filing → - Insider cluster2026-07-17
2 insiders bought $988,425 of PRQR in 30 days — 4.0σ above this company's 2-year norm
View source filing →
PRQR Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for ProQR Therapeutics N.V. (PRQR), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores PRQR at 37.8/100 on a 32-signal composite quality model, placing it at rank #2,221 of 2,962 stocks — the bottom half of the AI-ranked universe. Top institutional holders of PRQR by reported 13-F value include ADAGE CAPITAL PARTNERS GP, L.L.C., abrdn plc, Affinity Asset Advisors, based on the most recent SEC filings. PRQR trades on the Nasdaq exchange and files with the SEC under CIK 1612940. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PRQR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ProQR Therapeutics N.V. directly from SEC EDGAR. ProQR Therapeutics N.V.'s 13F Pro composite quality score has ranged between 36 and 40 since 2026, currently 37.8 — a stable long-term trajectory across 47 quarterly and live scoring snapshots.
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
Total Assets
-32.9% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $1.4M | — |
| Total Assets | $112.8M -32.9% | $168.0M +21.8% | $137.9M -19.5% | $171.3M -18.3% | $209.6M +112.3% | $98.7M |
Get alerted when PRQR's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for ProQR Therapeutics N.V. including:
Top Institutional Holders of PRQR
ADAGE CAPITAL PARTNERS GP, L.L.C.
$16.8M9,015,897 shabrdn plc
$16.6M8,932,507 shAffinity Asset Advisors, LLC
$10.3M5,543,936 shPrivium Fund Management B.V.
$10.3M5,520,024 shIkarian Capital, LLC
$6.4M3,425,930 shWoodline Partners LP
$6.1M3,277,143 shHEIGHTS CAPITAL MANAGEMENT, INC
$5.1M2,762,430 shMORGAN STANLEY
$3.3M1,767,215 shSPHERA FUNDS MANAGEMENT LTD.
$3.3M1,757,458 shKynam Capital Management, LP
$2.9M1,566,317 sh
| Fund | Value | Shares |
|---|---|---|
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $16.8M | 9,015,897 |
| abrdn plc | $16.6M | 8,932,507 |
| Affinity Asset Advisors, LLC | $10.3M | 5,543,936 |
| Privium Fund Management B.V. | $10.3M | 5,520,024 |
| Ikarian Capital, LLC | $6.4M | 3,425,930 |
| Woodline Partners LP | $6.1M | 3,277,143 |
| HEIGHTS CAPITAL MANAGEMENT, INC | $5.1M | 2,762,430 |
| MORGAN STANLEY | $3.3M | 1,767,215 |
| SPHERA FUNDS MANAGEMENT LTD. | $3.3M | 1,757,458 |
| Kynam Capital Management, LP | $2.9M | 1,566,317 |
Companies Similar to PRQR
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Cue Biopharma, Inc.
Inventiva S.A.
MACROGENICS INC
Ultragenyx Pharmaceutical Inc.
ASSEMBLY BIOSCIENCES, INC.
Legend Biotech Corp
ANAPTYSBIO, INC
C4 Therapeutics, Inc.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put PRQR on your watchlist
Track score changes the day ProQR Therapeutics N.V. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is PRQR a good stock to buy?
13F Pro's AI-powered analysis of ProQR Therapeutics N.V. (PRQR) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for PRQR are available on the PRQR stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. PRQR is classified as a small company.
Which hedge funds own PRQR?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling PRQR. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of ProQR Therapeutics N.V.'s investment landscape.